A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.

Also called NCT05255094

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 464 participants (enrolled count) (from the registry)
Sponsor
  • Akeso Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05255094
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05255094. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-03 (actual); primary completion 2022-06-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Biological)
AK102
Intervention (Biological)
AK102
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Akeso (class: industry)

Record details

Record id
cardio:ct-nct05255094
Content hash
b2a34dbb05f398e8d353483f651274b097c9355cb2fac1c5449d089215761c6b